Related Experiment Video
Updated: Apr 14, 2026

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9
Mar Hernandez-Guillamon1, Stephanie Mawhirt2, Steven Blais3
1From the Departments of Pathology, the Neurovascular Research Laboratory, Institut de Recerca, 08035 Barcelona, Spain.
Abstract:
Matrix metalloproteases (MMPs) MMP-2 and MMP-9 have been implicated in the physiological catabolism of Alzheimer's amyloid-β (Aβ). Conversely, their association with vascular amyloid deposits, blood-brain barrier disruption, and hemorrhagic transformations after ischemic stroke also highlights their involvement in pathological processes. To better understand this dichotomy, recombinant human (rh) MMP-2 and MMP-9 were incubated with Aβ40 and Aβ42, and the resulting proteolytic fragments were assessed via immunoprecipitation and quantitative mass spectrometry. Both MMPs generated Aβ fragments truncated only at the C terminus, ending at positions 34, 30, and 16. Using deuterated homologues as internal standards, we observed limited and relatively slow degradation of Aβ42 by rhMMP-2, although the enzyme cleaved >80% of Aβ40 during the 1st h of incubation. rhMMP-9 was significantly less effective, particularly in degrading Aβ(1-42), although the targeted peptide bonds were identical. Using Aβ(1-34) and Aβ(1-30), we demonstrated that these peptides are also substrates for both MMPs, cleaving Aβ(1-34) to produce Aβ(1-30) first and Aβ(1-16) subsequently. Consistent with the kinetics observed with full-length Aβ, rhMMP-9 degraded only a minute fraction of Aβ(1-34) and was even less effective in producing Aβ(1-16). Further degradation of Aβ(1-16) by either MMP-2 or MMP-9 was not observed even after prolonged incubation times. Notably, all MMP-generated C-terminally truncated Aβ fragments were highly soluble and did not exhibit fibrillogenic properties or induce cytotoxicity in human cerebral microvascular endothelial or neuronal cells supporting the notion that these truncated Aβ species are associated with clearance mechanisms rather than being key elements in the fibrillogenesis process.
Insights
Matrix metalloproteases (MMPs) like MMP-2 and MMP-9 can break down amyloid-beta (Aβ) into soluble fragments. These fragments are not prone to forming fibrils, suggesting a role for MMPs in Aβ clearance pathways.
Area of Science:
- Biochemistry
- Neuroscience
- Molecular Biology
Background:
- Matrix metalloproteases (MMPs), specifically MMP-2 and MMP-9, are involved in both normal amyloid-beta (Aβ) breakdown and pathological processes like Alzheimer's disease and stroke.
- The dual role of MMPs in Aβ metabolism necessitates a deeper understanding of their specific actions on Aβ peptides.
Purpose of the Study:
- To investigate the proteolytic activity of recombinant human (rh) MMP-2 and rhMMP-9 on different forms of amyloid-beta (Aβ).
- To characterize the resulting Aβ fragments and assess their potential for aggregation and cytotoxicity.
Main Methods:
- Incubation of Aβ40 and Aβ42 with rhMMP-2 and rhMMP-9.
- Analysis of proteolytic fragments using immunoprecipitation and quantitative mass spectrometry.
- Assessment of truncated Aβ fragment solubility, fibrillogenic potential, and cytotoxicity in cellular models.
Main Results:
- Both MMP-2 and MMP-9 generated C-terminally truncated Aβ fragments (ending at positions 34, 30, and 16).
- MMP-2 efficiently degraded Aβ40 but showed limited degradation of Aβ42, while MMP-9 was less effective overall, especially on Aβ42.
- Truncated Aβ fragments were highly soluble, non-fibrillogenic, and non-cytotoxic to endothelial and neuronal cells.
Conclusions:
- MMP-2 and MMP-9 cleave Aβ into soluble, non-pathogenic fragments, indicating a potential role in Aβ clearance.
- The observed degradation patterns suggest that MMPs contribute to the removal of Aβ rather than its aggregation and toxicity.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Export of Misfolded Proteins out of the ER

